Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids

Ian M. Copple,*† Luke M. Shelton,* Joanne Walsh,* Denise V. Kratschmar,† Adam Lister,† Alex Odermatt,† Christopher E. Goldring,* Albena T. Dinkova-Kostova,† Tadashi Honda,† and B. Kevin Park*†

*MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, UK; †Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, CH-4056 Basel, Switzerland; ‡Jacqui Wood Cancer Centre, Division of Cancer Research, Medical Research Institute, University of Dundee, Dundee DD1 9SY, UK; and §Department of Chemistry and Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York 11794

Received January 27, 2014; accepted April 22, 2014

© Published by Oxford University Press on behalf of Toxicological Sciences.

The transcription factor Nrf2 protects against a number of experimental pathologies, and is a promising therapeutic target. The clinical investigation of a potent Nrf2-inducing agent, the triterpenoid (TP) bardoxolone methyl (BARD), was recently halted due to adverse cardiovascular events in chronic kidney disease patients, although the underlying mechanisms are yet to be resolved. The majority of small molecule Nrf2 inducers are electrophilic and trigger Nrf2 accumulation via the chemical modification of its redox-sensitive repressor Keap1. Therefore, it is pertinent to question whether the therapeutic targeting of Nrf2 could be hindered in many cases by the inherent reactivity of a small molecule inducer toward unintended cellular targets, a key mechanism of drug toxicity. Using H4IIE-ARE8L hepatoma cells, we have examined the relationship between (a) Nrf2 induction potency, (b) toxicity and (c) in vitro therapeutic index (ratio of b:a) for BARD and a number of other small molecule activators of Nrf2. We show that BARD exhibits the highest potency toward Nrf2 and the largest in vitro therapeutic index among compounds that have been investigated clinically (namely BARD, sulforaphane and dimethyl fumarate). Through further examination of structurally related TPs, we demonstrate that an increase in potency toward Nrf2 is associated with a relatively smaller increase in toxicity, indicating that medicinal chemistry can be used to enhance the specificity of a compound as an inducer of Nrf2 signaling whilst simultaneously increasing its therapeutic index. These findings will inform the continuing design and development of drugs targeting Nrf2.

Key words: Nrf2; triterpenoids; therapeutic index.

Conversely, genetic or pharmacological activation of Nrf2 signaling has shown promise as a strategy for the prevention of a number of pathologies in animal models, prompting interest in the design and development of small molecule inducers of the Nrf2 pathway as novel drug candidates in a variety of clinical contexts (Suzuki et al., 2013). However, it is established that the majority of compounds that stimulate Nrf2 signaling are thiol-reactive (Dinkova-Kostova et al., 2001; Talalay et al., 1988) and capable of modifying cysteine residues in Keap1, the main cytosolic repressor of Nrf2 (Bryan et al., 2013), whilst many existing and withdrawn drugs are known to provoke off-target toxic effects through the generation of electrophilic reactive metabolites (Park et al., 2011). For example, the commonly used analgesic acetaminophen provokes hepatocellular necrosis when taken in overdose, due to the formation of a reactive quinoneimine that depletes glutathione, leading to the covalent modification of numerous macromolecules and the induction of oxidative stress (Hinson et al., 2010). Therefore, it is possible that the pharmacological targeting of Nrf2 could be hindered in many cases by the inherent reactivity of a small molecule inducer toward unintended cellular targets, in addition to Keap1, provoking therapy-limiting toxicity.

Until recently, one of the most promising candidates for a novel therapy based at least partly on the activation of Nrf2 was bardoxolone methyl (BARD). This thiol-reactive triterpenoid (TP) (Couch et al., 2005), known to be one of the most potent small molecule inducers of Nrf2 signaling (Dinkova-Kostova et al., 2005), triggered the improvement of renal function in patients with moderate to severe chronic kidney disease (CKD) and type 2 diabetes (Pergola et al., 2011). However, in 2012, a phase III clinical trial of BARD in patients with severe CKD was prematurely terminated, due to a high incidence of cardiovascular-related adverse events and deaths in the treatment arm, for which the underlying mechanism is currently unknown (de Zeeuw et al., 2013). It has been suggested that such a patient cohort was not the most appropriate for intervention.
FIG. 1. Concept of the in vitro therapeutic index. By calculating the concentrations of a compound that provoke a twofold increase in the activity of the Nrf2-sensitive ARE8L reporter transgene (hereafter referred to as the CD value) and a twofold decrease in cellular ATP content (hereafter referred to as the LC50 value) in H4IE-ARE8L cells, the in vitro therapeutic index (ratio of LC50 divided by CD) can be determined. (A) Example of a hypothetical compound exhibiting a relatively large in vitro therapeutic index, due to its high potency toward Nrf2 (i.e., low CD value) and minimal toxicity (i.e., high LC50 value). (B) Example of a hypothetical compound exhibiting a relatively small in vitro therapeutic index, due to its low potency toward Nrf2 (i.e., high CD value) and high toxicity (i.e., low LC50 value). This concept has been used to examine the relationship between Nrf2 induction potency, toxicity, and in vitro therapeutic index for a series of small molecule inducers of Nrf2.

FIG. 2. Chemical structures of the Nrf2 inducers used in this study. (A) Chemical structures of BARD, SUL and DMF, Nrf2 inducers that have entered the clinic. (B) Chemical structures of TP analogues of BARD.

with an Nrf2-targeting therapy, given that stimulation of Nrf2 signaling has been shown to prevent, but not reverse, a number of pathologies in laboratory studies (Zhang, 2013). Moreover, no significant adverse effects were reported in the phase II clinical trial of BARD in patients with diabetic nephropathy (Pergola et al., 2011), or a phase I clinical trial in patients with advanced solid tumors and lymphomas (Hong et al., 2012), despite the drug being administered at relatively high doses for up to a year. Therefore, it is unclear if the cardiovascular events attributed to BARD are intrinsic to the compound, or caused by unintended effects specific to severe CKD patients.

In order to assess whether the medicinal chemistry effort that resulted in the high potency of BARD as an inducer of Nrf2 signaling inadvertently produced a molecule that was intrinsi-
Cell culture. Rat H4IIE-ARE8L cells, stably expressing a luciferase reporter regulated by an eight-times repeated antioxidant response element, were generated as described previously (Kratschmar et al., 2012). Mouse Hepa-1c1c7 and human HepG2 cells were obtained from ATCC. Cells were maintained at 37°C in a 5% CO2 atmosphere in Dulbecco’s Modified Eagle’s Medium supplemented with 584 mg/l l-glutamine, 10% fetal bovine serum (Life Technologies, Paisley, UK). The media for H4IIE-ARE8L cells was further supplemented with 1mM HEPES and 1 × nonessential amino acids, whereas the media for Hepa-1c1c7 and HepG2 cells was further supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin. For drug treatments, compounds were dissolved in dimethyl sulfoxide (DMSO), with the concentration of the solvent in the media controlled to 0.5%.

Determination of ARE8L reporter activity. Following exposure of H4IIE-ARE8L cells to the indicated compounds for 24 h, reporter assays were performed essentially as described (Kratschmar et al., 2012), using the Bright-Glo Luciferase Assay System (Promega, Southampton, UK), in accordance with the manufacturer’s instructions. Data are normalized to the reporter activity detected in vehicle-exposed cells.

Determination of cellular ATP content. Following exposure of H4IIE-ARE8L, Hepa-1c1c7 or HepG2 cells to the indicated compounds for 24 h, cellular ATP content was quantified using the CellTiter-Glo Luminescent Cell Viability Assay (Promega), in accordance with the manufacturer’s instructions. Data are normalized to the ATP content of vehicle-exposed cells.

Calculation of in vitro therapeutic index. The concentrations of each compound that provoked a twofold increase in the activity of the ARE8L reporter transgene (CD value) and a twofold decrease in cellular ATP content (LC50 value) in H4IIE-ARE8L cells was determined by nonlinear regression analysis of the respective concentration-response curves, using GraphPad Prism 6 (GraphPad Software). The in vitro therapeutic index is expressed as a ratio of LC50 divided by CD.

Data analysis. Data are presented as the mean ± SD of three independent experiments. Pearson correlation coefficients were determined using GraphPad Prism 6.

RESULTS

BARD has a Large In Vitro Therapeutic Index Relative to other Clinically Validated Nrf2 Inducers

We first examined the relationship between the potency of BARD as an inducer of Nrf2 signaling and its ability to provoke cell death alongside SUL and DMF (Fig. 2), Nrf2 activators which have recently undergone patient trials in different disease contexts (Houghton et al., 2013; Lee et al., 2013). In order to enable a comparison of Nrf2 induction potency and toxicity within the same experimental setting, we used rat hepatoma H4IIE-ARE8L cells, which stably express an Nrf2-responsive luciferase transgene (Kratschmar et al., 2012). All

FIG. 3. Pharmacological potencies and toxicities of clinically validated Nrf2 inducers in H4IIE-ARE8L cells. Cells were exposed to the indicated concentrations of (A) BARD, (B) SUL, or (C) DMF for 24 h. Luciferase reporter activity (circles) and ATP content (squares) were subsequently quantified as readouts of Nrf2 induction and toxicity, respectively. Data represent mean ± SD, n = 3.
three compounds were able to enhance the activity of the Nrf2 reporter transgene, in a concentration-dependent manner, in H4IIE-ARE8L cells (Fig. 3). At higher concentrations, all three compounds triggered a loss of cell viability in H4IIE-ARE8L cells, concomitant with a loss of Nrf2 reporter transgene activity (Fig. 4), with CD values spanning four orders of magnitude (Table 1). Importantly, these CD values and the resulting rank order of potency toward Nrf2 were in excellent agreement with our previous structure-activity relationship (SAR) study of these compounds as inducers of NAD(P)H:quinone oxidoreductase 1 activity in Hepa-1c1c7 cells (Dinkova-Kostova et al., 2005), demonstrating the robustness of our analytical methods. With the exception of TP-72 (see below), the TPs induced loss of cell viability at micromolar concentrations (Fig. 4), with LC50 values spanning one order of magnitude (Table 1).

In keeping with the above observations, calculation of the in vitro therapeutic index for each TP confirmed that an increase in potency toward Nrf2 is associated with a relative enhancement of in vitro safety (Fig. 5, Table 1). Specifically, TP-151, TP-162, TP-225, and TP-319, which similarly to BARD contain an electron-withdrawing nitrile group (that increases the Michael reactivity) at C-2 on ring A, exhibited in vitro therapeutic indices 10–100 times greater than TP-222, which has a carboxyl group at this position (Table 1). Consistent with this, TP-198, which lacks the nitrile group and only contains an enone functionality, was shown to have an in vitro therapeutic index 300 times lower than BARD (Table 1). In addition, a second nitrile group at C-17 was shown to further increase the in vitro therapeutic index by 2–3 times (compare TP-225 with BARD and TP-151; Table 1). In contrast, a long side chain substituent (nine carbons) at the same position lowered the in vitro therapeutic index substantially; TP-233 was one of the least potent Nrf2 inducers and had the lowest in vitro therapeutic index among the TPs tested (Table 1). Although it was not possible to calculate an LC50 value and, therefore, an in vitro therapeutic index for TP-72, because it did not provoke loss of cellular ATP content at the highest possible concentration of 100 μM (Fig. 4), this compound exemplified the combined importance of the

### TABLE 1
Pharmacological Potencies, Toxicities and In Vitro Therapeutic Indices of Nrf2 Inducers in H4IIE-ARE8L Cells

|             | CD ($\mu$M) | LC50 ($\mu$M) | Therapeutic index |
|-------------|-------------|---------------|------------------|
| TP-225      | 0.0005 ± 0.0001 | 1.6 ± 0.2     | 3448.3 ± 698.2   |
| BARD        | 0.001 ± 0.0001 | 2.1 ± 0.5     | 1818.1 ± 356.3   |
| TP-162      | 0.02 ± 0.009  | 18.4 ± 4.6    | 1397.7 ± 415.1   |
| TP-151      | 0.01 ± 0.004  | 16.3 ± 3.7    | 1373.3 ± 201.5   |
| TP-319      | 0.005 ± 0.001 | 1.9 ± 0.2     | 417.7 ± 72.1     |
| SUL         | 0.4 ± 0.1     | 51.9 ± 2.6    | 140.6 ± 38.4     |
| TP-222      | 0.2 ± 0.02    | 7.2 ± 0.3     | 33.5 ± 2.1       |
| DMF         | 20.5 ± 8.7    | 184.4 ± 4.8   | 10.0 ± 3.7       |
| TP-198      | 1.6 ± 0.6     | 8.1 ± 1.4     | 5.5 ± 1.4        |
| TP-233      | 4.6 ± 2.1     | 10.4 ± 2.6    | 2.6 ± 1.4        |
| TP-72       | 29.1 ± 2.7    | N.D.          | N.D.             |

- aConcentration that provokes a twofold increase in ARE8L reporter transgene activity.
- bConcentration that provokes a twofold decrease in cellular ATP content.
- cRatio of LC50 divided by CD.
- dNot determined, due to lack of ATP depletion at the highest possible concentration (100 μM).

Chemical Tuning of TPs Enhances Nrf2 Induction Potency and In Vitro Therapeutic Index

To provide a chemical insight into the relationship between Nrf2 induction potency and toxicity of BARD, we expanded our analyses to include structurally related TPs (Fig. 2) which were previously shown to possess a range of chemical reactivities that correlated with potency as inducers of Nrf2 signaling (Bensasson et al., 2010). In keeping with this, we found that TP-72, TP-151, TP-198, TP-222, TP-225, TP-233, and TP-319 evoked concentration-dependent increases in Nrf2 reporter transgene activity in H4IIE-ARE8L cells (Fig. 4), with CD values spanning four orders of magnitude (Table 1). Importantly, these CD values and the resulting rank order of potency toward Nrf2 were in excellent agreement with our previous structure-activity relationship (SAR) study of these compounds as inducers of NAD(P)H:quinone oxidoreductase 1 activity in Hepa-1c1c7 cells (Dinkova-Kostova et al., 2005), demonstrating the robustness of our analytical methods. With the exception of TP-72 (see below), the TPs induced loss of cell viability at micromolar concentrations (Fig. 4), with LC50 values spanning one order of magnitude (Table 1).

In keeping with the above observations, calculation of the in vitro therapeutic index for each TP confirmed that an increase in potency toward Nrf2 is associated with a relative enhancement of in vitro safety (Fig. 5, Table 1). Specifically, TP-151, TP-162, TP-225, and TP-319, which similarly to BARD contain an electron-withdrawing nitrile group (that increases the Michael reactivity) at C-2 on ring A, exhibited in vitro therapeutic indices 10–100 times greater than TP-222, which has a carboxyl group at this position (Table 1). Consistent with this, TP-198, which lacks the nitrile group and only contains an enone functionality on this ring, was shown to have an in vitro therapeutic index 300 times lower than BARD (Table 1). In addition, a second nitrile group at C-17 was shown to further increase the in vitro therapeutic index by 2–3 times (compare TP-225 with BARD and TP-151; Table 1). In contrast, a long side chain substitution (nine carbons) at the same position lowered the in vitro therapeutic index substantially; TP-233 was one of the least potent Nrf2 inducers and had the lowest in vitro therapeutic index among the TPs tested (Table 1). Although it was not possible to calculate an LC50 value and, therefore, an in vitro therapeutic index for TP-72, because it did not provoke loss of cellular ATP content at the highest possible concentration of 100 μM (Fig. 4), this compound exemplified the combined importance of the
FIG. 4. Pharmacological potencies and toxicities of triterpenoids in H4IE-ARE8L cells. Cells were exposed to the indicated concentrations of (A) TP-72, (B) TP-151, (C) TP-162, (D) TP-198, (E) TP-222, (F) TP-225, (G) TP-233, or (H) TP-319 for 24 h. Luciferase reporter activity (circles) and ATP content (squares) were subsequently quantified as readouts of Nrf2 induction and toxicity, respectively. Data represent mean + SD, n = 3.
FIG. 5. Correlation between potency toward Nrf2, toxicity and in vitro therapeutic index of Nrf2 inducers in H4IIE-ARE8L cells. Correlation between potency toward Nrf2 and (A) toxicity [Pearson correlation coefficient 0.74, $p = 0.014$] or (B) in vitro therapeutic index [Pearson correlation coefficient $-0.925$, $p = 0.0001$] of clinically validated Nrf2 inducers (squares) and TPs (circles). CD and LC50 values and therapeutic index for each compound were calculated as described.

The delay between the decision of the Independent Data Monitoring Committee to stop the phase III clinical trial of BARD in patients with severe CKD “for safety concerns due to excess serious adverse events and mortality” and the recent publication of the study data (de Zeeuw et al., 2013) provided opportunity for both speculation surrounding the exact nature of the adverse events and commentary on the implications of the trial failure for targeting Nrf2 in the clinic (Rossing, 2013; Tayek and Kalantar-Zadeh, 2013; Zhang, 2013). In light of the well-established chemical properties (i.e., electrophilicity and reactivity with protein thiols) of the majority of Nrf2 inducers, it was pertinent to question whether the therapeutic targeting of Nrf2 could be undermined by the inherent reactivity of a small molecule inducer toward unintended cellular targets, a key mechanism of drug toxicity (Park et al., 2011). Here, we have examined this concept from a chemical perspective, in a model cell system, by defining the relationship between the potency of a compound as an inducer of Nrf2 and its in vitro therapeutic index, for molecules that have entered the clinic (BARD, SUL, and DMF) and a representative selection of TPs.

The principal finding of this study is that medicinal chemistry can be used to enhance the potency of a compound toward Nrf2 without adversely affecting its in vitro therapeutic index. Indeed, for the compounds studied here, we have demonstrated that an increase in Nrf2 induction potency across four orders of magnitude is accompanied by an increase in toxicity across just two orders of magnitude (Fig. 5A), and therefore an effective overall enhancement of in vitro safety (Fig. 5B). The fact that these conclusions apply to a series of structurally related compounds (BARD and the other TPs) as well as structurally distinct molecules (SUL and DMF) implies that our findings are likely applicable to a range of Nrf2 inducers, and indicate that Nrf2 potency is determined not by universal reactivity toward protein thiols, but via specific reactivity with a critical target, likely Keap1. Indeed, SUL and DMF (or, more precisely, its major intracellular metabolite monomethylfumarate) have been shown to directly modify specific cysteine residues in Keap1 (Hu et al., 2011; Linker et al., 2011), and we have previously demonstrated that TP-225 can interact with purified recombinant Keap1 in vitro (Dinkova-Kostova et al., 2005). Therefore, the identification of potent Nrf2 inducers may be supported by the in silico or in vitro screening of compound reactivity toward Keap1, as described recently (Hu et al., 2012; Wu et al., 2010), although in silico approaches would be considerably aided by the resolution of the full-length crystal structure of Keap1.

Notably, TP-225, and not BARD, exhibited the largest in vitro therapeutic index of the TPs (and indeed all of the compounds) studied here. Consistent with our contention that potency toward Nrf2 is the major contributory factor in the determination of in vitro safety, to our knowledge TP-225 is the most potent inducer of Nrf2 reported to date (Dinkova-Kostova et al., 2005). We have previously demonstrated the chemopreventive...
efficacy of TP-225 in SKH-1 hairless mice exposed to ultraviolet B radiation, in which topical application of the compound was shown to stimulate Nrf2 signaling and reduce the appearance of premalignant lesions and the volume of malignant tumors (Dinkova-Kostova et al., 2008). Despite these promising properties, the development of TP-225 as a therapeutic agent has been hindered by its poor oral bioavailability (unpublished data).

Determination of the in vitro therapeutic index provides an informative means of comparing the relationship between Nrf2 induction potency and toxicity for a number of compounds within a stable cell system. However, it cannot indicate with any degree of certainty that a compound will or will not provoke adverse reactions in animals and humans. Many clinical drug toxicities are underpinned by complex mechanisms involving species-specific drug disposition, interactions between different cell types, or unexpected biological perturbations in specific disease cohorts. Therefore, the balance between pharmacological potency, therapeutic efficacy, and toxicity is likely to be considerably different in vivo than in our in vitro system. Indeed, although DMF exhibited one of the lowest in vitro therapeutic indices here, this compound has recently been licensed for the management of multiple sclerosis (Lee et al., 2013), whereas BARD has recently been shown to provoke adverse cardiovascular events in CKD patients (de Zeeuw et al., 2013), despite it demonstrating one of the highest in vitro therapeutic indices in this study. Although these observations could indicate that high Nrf2 induction potency/Keap1 specificity is associated with worse clinical outcome and/or increased risk of adverse events in patients, two factors argue against this. Firstly, the relatively limited clinical experience of using Nrf2 inducers (BARD, SUL, and DMF) in different disease contexts (CKD, cancer, and multiple sclerosis) makes it difficult, at this stage, to draw conclusions about the precise relationship between Nrf2 induction potency and clinical efficacy for a given compound. Secondly, the lack of significant toxicity, particularly of a cardiovascular nature, in a recent year-long phase I clinical trial of BARD in cancer patients (Hong et al., 2012) suggests that the adverse reactions observed in CKD patients are driven by unforeseen effects of the drug in this specific patient cohort (which are known to be predisposed to cardiovascular disease), rather than via chronic activation of Nrf2 per se. This contention is further supported by the recent commencement of a phase II clinical trial of BARD in patients with pulmonary arterial hypertension (NCT02036970).

TPs are known to target numerous biological processes (Liby and Sporn, 2012), and it has yet to be proven, to our knowledge, that induction of Nrf2 has a direct mechanistic role in the clinical actions of BARD in CKD patients, although Nrf2 has been shown to be protective in animal models of renal disease (Ruíz et al., 2013; Shelton et al., 2013). An understanding of whether BARD provokes cardiovascular dysfunction in CKD patients by direct (e.g., cytotoxicity toward a particular cell type) or indirect (e.g., via hypomagnesemia or blood pressure perturbation) means will inform detailed mechanistic studies in relevant model systems, which could further distinguish undesirable compound-patient interactions from generic deleterious effects. Such studies will provide insights into the human biological factors that modulate the efficacy and safety of Nrf2 inducers in vivo. This in turn could lead to the development of more sophisticated model cell systems that could be used in the early development of novel Nrf2 inducers for specific clinical indications and target patient populations.

**SUPPLEMENTARY DATA**

Supplementary data are available online at http://toxsci.oxfordjournals.org/.

**FUNDING**

Medical Research Council as part of the Centre for Drug Safety Science (G070065/4); European Community Innovative Medicines Initiative as part of the MIP-DILI project (115336); Cancer Research UK (C20953/A10270); Reata Pharmaceuticals.

**REFERENCES**

Bensasson, R. V., Zoete, V., Berthier, G., Talalay, P., and Dinkova-Kostova, A. T. (2010). Potency ranking of triterpenoids as inducers of a cytoprotective enzyme and as inhibitors of a cellular inflammatory response via their electron affinity and their electrophilicity index. *Chem. Biol. Interact.* 186, 118–126.

Bryan, H. K., Olayanju, A., Goldring, C. E., and Park, B. K. (2013). The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. *Biochem. Pharmacol.* 85, 705–717.

Copple, I. M., Goldring, C. E., Kitteringham, N. R., and Park, B. K. (2008). The Nrf2-Keap1 defence pathway: Role in protection against drug-induced toxicity. *Toxicology* 246, 24–33.

Couch, R. D., Browning, R. G., Honda, T., Gribble, G. W., Wright, D. L., Sporn, M. B., and Anderson, A. C. (2005). Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: Implications for a molecular mechanism of action. *Biorg. Med. Chem. Lett.* 15, 2215–2219.

de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013). Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. *N. Engl. J. Med.* 369, 2492–2503.

Dinkova-Kostova, A. T., Jenkins, S. N., Wehage, S. L., Huse, D. L., Benedict, A. L., Stephenson, K. K., Fahey, J. W., Liu, H., Liby, K. T., Honda, T., et al. (2008). A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice. *Biochem. Biophys. Res. Commun.* 367, 859–865.

Dinkova-Kostova, A. T., Liby, K. T., Stephenson, K. K., Holtclaw, W. D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005). Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. *Proc. Natl. Acad. Sci. U.S.A.* 102, 4584–4589.
Dinkova-Kostova, A. T., Massiah, M. A., Bozak, R. E., Hicks, R. J., and Talalay, P. (2001). Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. U.S.A. 98, 3404–3409.

Hinson, J. A., Roberts, D. W., and James, L. P. (2010). Mechanisms of acetaminophen-induced liver necrosis. Handb. Exp. Pharmacol. 196, 369–405.

Honda, T., Honda, Y., Favaloro, F. G., Jr, Gribble, G. W., Suh, N., Place, A. E., Rendi, M. H., and Sporn, M. B. (2002). A novel dicyanotriterpenoid, 2-cyano-3,12-dioxoolean-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett. 12, 1027–1030.

Honda, T., Rounds, B. V., Bore, L., Finlay, H. J., Favaloro, F. G., Jr, Suh, N., Wang, Y., Sporn, M. B., and Gribble, G. W. (2000). Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43, 4234–4246.

Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012). A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18, 3396–3406.

Houghton, C. A., Fassett, R. G., and Coombes, J. S. (2013). Sulforaphane: Translational research from laboratory bench to clinic. Nutr. Rev. 71, 709–726.

Hu, C., Eggerl, A. L., Mesecar, A. D., and van Breenen, R. B. (2011). Modification of keap1 cysteine residues by sulforaphane. Chem. Res. Toxicol. 24, 515–521.

Hu, C., Nikolic, D., Eggerl, A. L., Mesecar, A. D., and van Breenen, R. B. (2012). Screening for natural chemoprevention agents that modify human Keap1. Anal. Biochem. 421, 108–114.

Kratschmar, D. V., Calabrese, D., Walsh, J., Lister, A., Birk, J., Appenzeller-Herzog, C., Moulin, P., Goldring, C. E., and Odermatt, A. (2012). Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11beta-HSD1-mediated glucocorticoid activation in hepatic cells. PLoS One 7, e36774.

Lee, D. H., Stangel, M., Gold, R., and Linker, R. A. (2013). The fumaric acid ester BG-12: A new option in MS therapy. Expert Rev. Neurother. 13, 951–958.

Liby, K. T., and Sporn, M. B. (2012). Synthetic oleanane triterpenoids: Multi-functional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 64, 972–1003.

Linker, R. A., Lee, D. H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., Honronovsky, X., Buku, A., Chollate, S., et al. (2011). Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3), 678–692.

Ma, Q. (2013). Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53, 401–426.

Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naish, D. J., Nelson, S., et al. (2011). Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 10, 292–306.

Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327–336.

Rossier, P. (2013). Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted? Nat. Rev. Nephrol. 9, 128–130.

Ruiz, S., Pergola, P. E., Zager, R. A., and Vaziri, N. D. (2013). Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 83, 1029–1041.

Shelton, L. M., Park, B. K., and Copple, I. M. (2013). Role of Nrf2 in protection against acute kidney injury. Kidney Int. 84, 1090–1095.

Suzuki, T., Motohashi, H., and Yamamoto, M. (2013). Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 34, 340–346.

Talalay, P., De Long, M. J., and Prochaska, H. J. (1988). Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 85, 8261–8265.

Tayek, J. A., and Kalantar-Zadeh, K. (2013). The extinguished BEACON of bardoxolone: Not a Monday morning quarterback story. Am. J. Nephrol. 37, 208–211.

Wu, J. H., Miao, W., Hu, L. G., and Batist, G. (2010). Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1. Chem. Biol. Drug Des. 75, 475–480.

Zhang, D. D. (2013). Bardoxolone brings Nrf2-based therapies to light. Antioxid. Redox Signal. 19, 517–518.